Plasma Kallikrein Binding Proteins for Active-Form Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases associated with plasma kallikrein activity, such as hereditary angioedema and various inflammatory and cardiovascular conditions, lack specificity and efficacy due to the use of small molecule serine proteases, leading to potential side effects and frequent dosing requirements.
Innovation Solution
Development of plasma kallikrein binding proteins, particularly antibodies, that selectively target the active form of plasma kallikrein without binding to its precursor, offering high potency, specificity, and prolonged serum residency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule serine proteases are used to inhibit plasma kallikrein, then the treatment can be administered, but the specificity is insufficient leading to side effects and frequent dosing requirements
Solution Approach 1:
The patent changes the molecular size and structural parameters from small molecules to large antibody molecules. This parameter change enables the inhibitor to achieve high specificity for plasma kallikrein by recognizing unique epitopes on the active form, thereby reducing side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs composite antibody structures combining heavy and light chains with specific complementarity-determining regions (CDRs) to create a multi-component inhibitory system. This composite structure enables sophisticated epitope recognition and binding, achieving superior specificity compared to simple small molecule inhibitors.
2Productivity
If small molecule serine proteases are used, then the treatment can be administered, but frequent dosing is required due to short serum residency
Solution Approach 1:
The patent fundamentally changes the size parameter of the therapeutic agent from small molecule to antibody-scale large molecule. This parameter change extends serum half-life through FcRn-mediated recycling and reduced renal clearance, enabling infrequent dosing schedules while maintaining continuous therapeutic activity.
3Reliability
If inhibitors bind to the active form of plasma kallikrein, then plasma kallikrein activity is inhibited, but the precursor prekallikrein may also be affected
Solution Approach 1:
The patent applies local quality by designing antibodies with CDRs that recognize specific local epitopes on the active form of plasma kallikrein, such as the hinge region or catalytic site. This localized recognition ensures high-affinity binding to the active enzyme while leaving the precursor prekallikrein unaffected, as it lacks these specific epitopes.
Solution Approach 2:
Instead of attempting to distinguish between active and inactive forms through complex conformational sensing, the patent inverts the approach by designing inhibitors that simply do not bind to the precursor form at all. The antibody is engineered to recognize only the active form's unique structural features, making the inactive precursor invisible to the inhibitor by design.
Data Source
AI summary
Plasma kallikrein binding proteins and methods of using such proteins are described.